A novel small molecule inhibitor of candida albicans biofilm formation, filamentation and virulence with low potential for the development of resistance

npj Biofilms and Microbiomes

Volumn 1, Issue , 2015, Pages

  Pierce, Christopher G ^a   Chaturvedi, Ashok K ^a   Lazzell, Anna L ^a   Powell, Alexander T ^a   Saville, Stephen P ^a   Mchardy, Stanton F ^a   Lopez Ribot, Jose L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85016287158     PISSN: None     EISSN: 20555008     Source Type: Journal    
DOI: 10.1038/npjbiofilms.2015.12     Document Type: Article

References (50)

1. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med 2012; 4: 165rv113.
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
3. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-1527.
4. Wenzel RP. Health care-Associated infections: major issues in the early years of the 21st century. Clin Infect Dis 2007; 45(Suppl 1): S85-S88.
5. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-Acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642-2645.
6. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
7. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385-5394.
8. Desai JV, Mitchell AP, Andes DR. Fungal biofilms, drug resistance, and recurrent infection. Cold Spring Harbor Perspect Med 2014; 4: A019729; doi:10.1101/cshperspect.a019729.
9. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004; 17: 255-267.
10. Ramage G, Martinez JP, Lopez-Ribot JL. Candida biofilms on implanted biomaterials: A clinically significant problem. FEMS Yeast Res 2006; 6: 979-986.
11. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-1177.
12. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010; 9: 719-727.
13. Pierce CG, Lopez-Ribot JL. Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Exp Opin Drug Discov 2013; 8: 1117-1126.
14. Roemer T, Krysan DJ. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harbor Perspect Med 2014; 4: A019703; doi:10.1101/cshperspect.a01973.
15. Pierce CG, Srinivasan A, Uppuluri P, Ramasubramanian AK, Lopez-Ribot JL. Antifungal therapy with an emphasis on biofilms. Curr Opin Pharmacol 2013; 13: 726-730.
16. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002; 2: 73-85.
17. Gillum AM, Tsay EY, Kirsch DR. Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 1984; 198: 179-182.
18. Hernandez S, Lopez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004; 48: 1382-1383.
19. Li X, Brown N, Chau AS, Lopez-Ribot JL, Ruesga MT, Quindos G et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 2004; 53: 74-80.
20. Pierce CG, Uppuluri P, Tristan AR, Wormley FL Jr., Mowat E, Ramage G et al. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc 2008; 3: 1494-1500.
21. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001; 45: 2475-2479.
22. Gerets HH, Hanon E, Cornet M, Dhalluin S, Depelchin O, Canning M et al. Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: A preliminary study using a multiplexing approach. Toxicology In Vitro 2009; 23: 319-332.
23. Schoonen WG, de Roos JA, Westerink WM, Debiton E. Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II mechanistic assays on NAD(P)H, ATP and DNA contents. Toxicology In Vitro 2005; 19: 491-503.
24. Uppuluri P, Nett J, Heitman J, Andes D. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 2008; 52: 1127-1132.
25. Solis NV, Filler SG. Mouse model of oropharyngeal candidiasis. Nat Protoc 2012; 7: 637-642.
26. Takakura N, Sato Y, Ishibashi H, Oshima H, Uchida K, Yamaguchi H et al. A novel murine model of oral candidiasis with local symptoms characteristic of oral thrush. Microbiol Immunol 2003; 47: 321-326.
27. You J, Du L, King JB, Hall BE, Cichewicz RH. Small-molecule suppressors of Candida albicans biofilm formation synergistically enhance the antifungal activity of amphotericin B against clinical Candida isolates. ACS Chem Biol 2013; 8: 840-848.
28. Fazly A, Jain C, Dehner AC, Issi L, Lilly EA, Ali A et al. Chemical screening identifies filastatin, a small molecule inhibitor of Candida albicans adhesion, morphogenesis, and pathogenesis. Proc Natl Acad Sci USA 2013; 110: 13594-13599.
29. LaFleur MD, Lucumi E, Napper AD, Diamond SL, Lewis K. Novel high-Throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms. J Antimicrob Chemother 2011; 66: 820-826.
30. Siles SA, Srinivasan A, Pierce CG, Lopez-Ribot JL, Ramasubramanian AK. High-Throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. Antimicrob Agents Chemother 2013; 57: 3681-3687.
31. Srinivasan A, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. High-Throughput nano-biofilm microarray for antifungal drug discovery. mBio 2013; 4: E00331-13; doi:10.1128/mBio.00331-13.
32. Wong SS, Kao RY, Yuen KY, Wang Y, Yang D, Samaranayake LP et al. In vitro and in vivo activity of a novel antifungal small molecule against Candida infections. PLoS ONE 2014; 9: E85836.
33. Goodnow RA Jr. Current practices in generation of small molecule new leads. J Cell Biochem Suppl 2001; (Suppl 37): 13-21.
34. Lazzell AL, Chaturvedi AK, Pierce CG, Prasad D, Uppuluri P, Lopez-Ribot JL. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother 2009; 64: 567-570.
35. Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM, Hernday AD et al. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 2012; 148: 126-138.
36. Nobile CJ, Mitchell AP. Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol 2006; 8: 1382-1391.
37. Ramage G, VandeWalle K, Lopez-Ribot JL, Wickes BL. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett 2002; 214: 95-100.
38. Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence 2013; 4: 119-128.
39. Saville SP, Lazzell AL, Bryant AP, Fretzen A, Monreal A, Solberg EO et al. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob Agents Chemother 2006; 50: 3312-3316.
40. Saville SP, Lazzell AL, Monteagudo C, Lopez-Ribot JL. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell 2003; 2: 1053-1060.
41. Sudbery PE. Growth of Candida albicans hyphae. Nat Rev Microbiol 2011; 9: 737-748.
42. Shareck J, Belhumeur P. Modulation of morphogenesis in Candida albicans by various small molecules. Eukaryot Cell 2011; 3: 3.
43. Tumbarello M, Posteraro B, Trecarichi EM, Fiori B, Rossi M, Porta R et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 2007; 45: 1843-1850.
44. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: A new paradigm for antimicrobial therapy. Nat Chem Biol 2007; 3: 541-548.
45. Cowen LE, Sanglard D, Calabrese D, Sirjusingh C, Anderson JB, Kohn LM. Evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 2000; 182: 1515-1522.
46. Maccallum DM. Hosting infection: Experimental models to assay Candida virulence. Int J Microbiol 2012; 2012: 363764.
47. MacCallum DM, Coste A, Ischer F, Jacobsen MD, Odds FC, Sanglard D. Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. Antimicrob Agents Chemother 2010; 54: 1476-1483.
48. MacCallum DM, Odds FC. Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses 2005; 48: 151-161.
49. Spellberg B, Ibrahim AS, Edwards JE Jr, Filler SG. Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis 2005; 192: 336-343.
50. Spellberg B, Johnston D, Phan QT, Edwards JE Jr, French SW, Ibrahim AS et al. Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect Immun 2003; 71: 5756-5764.